In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report), with a price target of $15.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Nuvectis Pharma’s promising advancements in their oncology programs. The company reported a financial position with $29.9 million in cash, which is expected to support operations through 2027, indicating a stable financial runway. This financial stability is complemented by the progress in their two key programs, NXP800 and NXP900, which are advancing through clinical trials.
NXP800 is currently in a Phase 1b trial for ARID1a-mutated ovarian cancer, with updates anticipated soon, while NXP900 is being tested in YES1/SRC-driven solid tumors and in combination with other inhibitors for non-small cell lung cancer. The recent presentations at AACR ’25 provided strong scientific rationale for NXP900’s potential, showcasing its ability to inhibit tumor growth and its synergistic effects when combined with other cancer therapies. These developments underscore the potential of Nuvectis Pharma’s pipeline to address unmet medical needs in oncology, justifying the Buy rating.
In another report released on April 30, Maxim Group also reiterated a Buy rating on the stock with a $17.00 price target.